FindMyKOL
Clinical trialNCT05358691WithdrawnPhase 1Interventional

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

NCT05358691 is a phase 1 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it was withdrawn. It studies AN0025 in Lung Cancer Stage III. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2024 and a primary completion date of 1 Dec 2027. One of its registered investigators has a FindMyKOL profile.

SponsorRutgers, The State University of New JerseyEnrollment0Lung Cancer Stage III
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05358691
FieldValue
Registry IDNCT05358691
StatusWithdrawn
PhasePhase 1
Study typeInterventional trial
Lead sponsorRutgers, The State University of New Jersey
Enrollment0
Registered sites1
Countries1
ConditionsLung Cancer Stage III
DrugsAN0025
Start1 Nov 2024
Primary completion1 Dec 2027
Study completion1 Jun 2028
Last update posted16 Apr 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Primary * Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) * Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory * Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New Jersey, United States1 site
  • Rutgers Cancer Institute of New Jersey

    New Brunswick

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 1 siteNJ1ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AN0025
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05358691

Each answer restates registry values shown on this page.

What is NCT05358691?

NCT05358691 is a phase 1 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies AN0025 in Lung Cancer Stage III.

Who leads NCT05358691?

The registry names Salma K Jabbour, MD (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.

Where does NCT05358691 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05358691 study?

The registered drug and biological interventions are AN0025.

When did NCT05358691 end?

The registry lists a primary completion date of 1 Dec 2027 and a study completion date of 1 Jun 2028. The sponsor last updated the record on 16 Apr 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.